ANAPTYSBIO INC (ANAB) Stock Overview
NASDAQ:ANAB - US0327241065 - Common Stock
ANAB Key Statistics, Chart & Performance
The current stock price of ANAB is 20.33 USD. In the past month the price decreased by -17.66%. In the past year, price decreased by -46.63%.
ANAB Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 19.87 | 371.68B | ||
| AMGN | AMGEN INC | 13.19 | 154.89B | ||
| GILD | GILEAD SCIENCES INC | 14.6 | 140.17B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 23.08 | 100.25B | ||
| REGN | REGENERON PHARMACEUTICALS | 12.72 | 61.55B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 58.53B | ||
| ARGX | ARGENX SE - ADR | 76.83 | 43.59B | ||
| ONC | BEONE MEDICINES LTD-ADR | 6.16 | 36.38B | ||
| INSM | INSMED INC | N/A | 28.77B | ||
| BNTX | BIONTECH SE-ADR | N/A | 24.04B | ||
| NTRA | NATERA INC | N/A | 23.09B | ||
| BIIB | BIOGEN INC | 8.26 | 19.38B |
Related stock screener links
About ANAB
Company Profile
AnaptysBio, Inc. is a clinical stage biotechnology company. The company is headquartered in San Diego, California and currently employs 136 full-time employees. The company went IPO on 2017-01-26. The firm is focused on delivering immunology therapeutics for autoimmune and inflammatory diseases. The Company’s lead program, Rosnilimab, is a depleter and agonist targeting PD-1+ T cells, is in a Phase IIb trial for the treatment of rheumatoid arthritis and in a Phase II trial for the treatment of ulcerative colitis. The Company’s pipeline also includes ANB033, a CD122 antagonist, and ANB101, a blood dendritic cell antigen 2 (BDCA2) modulator, in Phase I trials. The company has also discovered multiple therapeutic antibodies licensed to GSK in a financial collaboration for immuno-oncology, including a PD-1 antagonist (Jemperli (dostarlimab-gxly)) and a TIM-3 antagonist (cobolimab, GSK4069889). Rosnilimab is an IgG1 antibody that directly targets PD-1+ T cells, resulting in their depletion or agonism, impacting pathogenic drivers of autoimmune and inflammatory diseases.
Company Info
ANAPTYSBIO INC
10770 Wateridge Circle, Suite 210
San Diego CALIFORNIA 92121 US
CEO: Hamza Suria
Employees: 136
Phone: 18583626295
ANAPTYSBIO INC / ANAB FAQ
What is the stock price of ANAPTYSBIO INC today?
The current stock price of ANAB is 20.33 USD. The price increased by 0.99% in the last trading session.
What is the ticker symbol for ANAPTYSBIO INC stock?
The exchange symbol of ANAPTYSBIO INC is ANAB and it is listed on the Nasdaq exchange.
On which exchange is ANAB stock listed?
ANAB stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for ANAPTYSBIO INC stock?
18 analysts have analysed ANAB and the average price target is 47.53 USD. This implies a price increase of 133.8% is expected in the next year compared to the current price of 20.33. Check the ANAPTYSBIO INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is ANAPTYSBIO INC worth?
ANAPTYSBIO INC (ANAB) has a market capitalization of 569.24M USD. This makes ANAB a Small Cap stock.
How many employees does ANAPTYSBIO INC have?
ANAPTYSBIO INC (ANAB) currently has 136 employees.
What are the support and resistance levels for ANAPTYSBIO INC (ANAB) stock?
ANAPTYSBIO INC (ANAB) has a support level at 20.25 and a resistance level at 20.34. Check the full technical report for a detailed analysis of ANAB support and resistance levels.
Is ANAPTYSBIO INC (ANAB) expected to grow?
The Revenue of ANAPTYSBIO INC (ANAB) is expected to grow by 79.78% in the next year. Check the estimates tab for more information on the ANAB EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy ANAPTYSBIO INC (ANAB) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of ANAB, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of ANAB, evaluating the profitability, health, valuation and growth aspects
- ANAPTYSBIO INC (ANAB) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- ANAPTYSBIO INC (ANAB) Sales and EPS estimates to see what analysts future expectations are.
- ANAPTYSBIO INC (ANAB) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- ANAPTYSBIO INC (ANAB) Insider and Institutional Ownership to learn about the owners and their transactions.
- ANAPTYSBIO INC (ANAB) Stock Chart to make your own analysis
- ANAPTYSBIO INC (ANAB) Latest news and press-releases to stay up to date.
Does ANAPTYSBIO INC (ANAB) stock pay dividends?
ANAB does not pay a dividend.
When does ANAPTYSBIO INC (ANAB) report earnings?
ANAPTYSBIO INC (ANAB) will report earnings on 2025-11-03, after the market close.
What is the Price/Earnings (PE) ratio of ANAPTYSBIO INC (ANAB)?
ANAPTYSBIO INC (ANAB) does not have a PE ratio as the earnings reported over the last twelve months were negative (-4.48).
What is the Short Interest ratio of ANAPTYSBIO INC (ANAB) stock?
The outstanding short interest for ANAPTYSBIO INC (ANAB) is 34.32% of its float. Check the ownership tab for more information on the ANAB short interest.
ANAB Technical Analysis
ANAB Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to ANAB. ANAB may be in some trouble as it scores bad on both profitability and health.
ANAB Financial Highlights
Over the last trailing twelve months ANAB reported a non-GAAP Earnings per Share(EPS) of -4.48. The EPS increased by 29.45% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -39.55% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
ANAB Forecast & Estimates
18 analysts have analysed ANAB and the average price target is 47.53 USD. This implies a price increase of 133.8% is expected in the next year compared to the current price of 20.33.
For the next year, analysts expect an EPS growth of 11.29% and a revenue growth 79.78% for ANAB